Table 4.
Subgroup analysis of efficacy according to tumor types
| Total | NSCLC | EC | GC | |
|---|---|---|---|---|
| Total | 90 | 22 | 19 | 12 |
| Best response | ||||
| CR | 0 | 0 | 0 | 0 |
| PR | 23 | 6 | 7 | 3 |
| SD | 45 | 14 | 7 | 7 |
| PD | 22 | 2 | 5 | 2 |
| ORR (%) | 25.6 | 27.3 | 36.8 | 25 |
| DCR (%) | 75.6 | 90.9 | 73.6 | 83.3 |
| mPFS (mo, 95% CI) | 5.53 (3.69–7.37) | 5.53 (0.96–10.10) | 4.97 (1.07–8.87) | 5.73 (3.25–8.21) |
| 6m‐PFS (%) | 45.8 | 48.9 | 48.1 | 32.1 |
| 12m‐PFS (%) | 25.1 | 36.7 | 16 | 21.4 |
| mOS (mo, 95% CI) | 16.9 (NR–NR) | NR | 9.43 (1.53–17.33) | NR |
| 6m‐OS (%) | 81.6 | 90.9 | 73.3 | 90.0 |
| 12m‐OS (%) | 58.1 | 65.9 | 48.9 | 70.0 |
| 18m‐OS (%) | 48.1 | 54.9 | 29.3 | 70.0 |
Abbreviations: CR, complete response; DCR, disease control rate; EC, esophageal cancer; GC, gastric cancer; mPFS, median progression‐free survival; mOS, median overall survival; NR, not reached; NSCLC, non‐small‐cell lung cancer; ORR: overall response rate; PD: progressive disease; PR, partial response; SD, stable disease.